Challenges and new horizons in the management of advanced basal cell carcinoma: A UK perspective

British Journal of Cancer

Volumn 111, Issue 8, 2014, Pages 1476-1481

  Lear, J T ^a   Corner, C ^b   Dziewulski, P ^c   Fife, K ^d   Ross, G L ^e   Varma, S ^f   Harwood, C A ^g  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

^c BROOMFIELD HOSPITAL   (United Kingdom)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

^e CHRISTIE HOSPITAL   (United Kingdom)

^f QUEEN S MEDICAL CENTRE   (United Kingdom)

^g QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOMA, BASAL CELL; HUMAN; SKIN NEOPLASMS; UNITED KINGDOM;

CARCINOMA, BASAL CELL; GREAT BRITAIN; HUMANS; SKIN NEOPLASMS;

EID: 84908892950     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.270     Document Type: Review

References (39)

1. Artis AHMM, Mosterd K, Essers BAB, Spoorenberg E, Sommer A, De Rooij MJM, van Pelt HPA, Quaedvlieg PJF, Krekels GAM, van Neer PAFA, Rijzewijk JJ, van Geest AJ, Steijlen PM, Nelemans PJ, Kelleners-Smeets NWJ (2013) Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basalcell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol 14: 647-654.
2. Avril MF, Auperin A, Margulis A, Gerbaulet A, Duvillard P, Benhamou E, Guillaume JC, Chalon R, Petit JY, Sancho-Garnier H, Prade M, Bouzy J, Chassagne D (1997) Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. Br J Cancer 76: 100-106.
3. Baxter JM, Patel AN, Varma S (2012) Facial basal cell carcinoma. Br Med J 345: e5342.
4. Castori M, Morrone A, Kanitakis J, Grammatico P (2012) Genetic skin diseases predisposing to basal cell carcinoma. Eur J Dermatol 22: 299-309.
5. Chakravarty EF, Michaud K, Wolfe F (2005) Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 32: 2130-2135.
6. Dummer R (2013) Treating basal-cell carcinoma in a real life setting. Lancet Oncol 14: 572-573.
7. Dreno B (2003) Skin cancers after transplantation. Nephrol Dial Transplant 18: 1502-1508.
8. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC Cancer Staging Manual ed 7, Springer: New York, pp 301-314.
9. Eibenschutz L, Marenda S, Buccini P, De Simone P, Ferrari A, Mariani G, Silipo V, Catricala C (2008) Giant and large basal cell carcinoma treated with topical photodynamic therapy. Eur J Dermatol 18: 663-666.
10. Fernandes H, Fernandes N, Bhattacharya S, Chen W, Seth A, Hameed M, Mirani N, Lambert WC (2010) Molecular signatures linked with aggressive behavior in basal cell carcinoma: a report of 6 cases. Am J Dermatopathol 32: 550-556.
11. Grob JJ, Kunstfeld R, Dreno B, Jouary T, Mortier L, Basset-Sequin N, Ascierto PA, Hansson J, Mitchell L, Starnawski M, Hauschild A (2013) Vismodegib, a hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study interim analysis in 300 patients. J Clin Oncol 31(Suppl): abstr 9036.
12. Gropper AB, Girouard SD, Hojman LP, Huang SJ, Qian X, Murphy GF, Vleugels RA (2012) Metastatic basal cell carcinoma of the posterior neck: case report and review of the literature. J Cutan Pathol 39: 526-534.
13. Jimeno A, Weiss GJ, Miller Jr WH, Gettinger S, Eigl BJC, Lynne A, Chang S, Dunbar J, Devens S, Faia K, Skliris G, Kutok J, Lewis KD, Tibes R, Sharfman WH, Ross RW, Rudin CM (2013) Phase I study of the hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res 19: 2766-2774.
14. Lear JT (2012) Oral hedgehog-pathway inhibitors for basal-cell carcinoma. N Engl J Med 366: 2225-2226.
15. Leger M, Quintana A, Tzu J, Yee H, Kamino H, Sanchez M (2011) Nevoid basal cell carcinoma syndrome. Dermatol Online J 17: 23.
16. Lin TL, Matsui W (2012) Hedgehog pathway as a drug target: smoothened inhibitors in development. Onco Targets Ther 5: 47-58.
17. Lomas A, Leonardi-Bee J, Bath-Hextall F (2012) A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 166: 1069-1080.
18. Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD (2010) Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 8: 268-274.
19. McCusker ME, Hou J, Wang L, Yue H, Hauschild A (2012) Metastatic basal cell carcinoma: differences in survival by site of spread. J Clin Oncol 30(suppl): abstr 8585.
20. Miller SJ (2000) The National Comprehensive Cancer Network (NCCN) guidelines of care for nonmelanoma skin cancers. Dermatol Surg 26: 289-292.
21. Mosterd K, Krekels GA, Nieman FH (2008) Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. Lancet Oncol 9: 1149-1156.
22. Rangwala S, Tsai KY (2011) Roles of the immune system in skin cancer. Br J Dermatol 165: 953-965.
23. Rowe DE, Carroll RJ, Day Jr. CL (1989) Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. J Dermatol Surg Oncol 15: 424-431.
24. Samarasinghe V, Madan V (2012) Nonmelanoma skin cancer. J Cutan Aesthet Surg 5: 3-10.
25. Scrivener Y, Grosshans E, Cribier B (2002) Variations of basal cell carcinomas according to gender, age, location and histopathological subtype. Br J Dermatol 147: 41-47.
26. Sekulic A, Migden MR, Basset-Seguin N, Grabe C, Gesierich A, Lao CD, Miller C, Mortier L, Murrell DF, Hamid O, Quevedo F, Schadendorf D, Hou J, Yue H (2013) Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): 18-month update of the pivotal ERIVANCE BCC study. J Clin Oncol 31(Suppl): abstr 9037.
27. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A (2012) Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 366: 2171-2179.
28. Silverman MK, Kopf AW, Bart RS, Grin CM, Levenstein MS (1992) Recurrence rates of treated basal cell carcinomas. Part 3: surgical excision. J Dermatol Surg Oncol 18: 471-476.
29. Skvara H, Kalthoff F, Meingassner JG, Wolff-Winiski B, Aschauer H, Kelleher JF, Wu X, Pan S, Mickel L, Schuster C, Stary G, Jalili A, David OJ, Emotte C, Antunes AM, Rose K, Decker J, Carlson I, Gardner H, Stuetz A, Bertolino AP, Stingl G, De Rie MA (2011) Topical treatment of basal cell carcinomas in nevoid basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol 131: 1735-1744.
30. Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, Coppola C, Chanana AM, Marji J, Bickers DR, Epstein Jr EH (2012) Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 366: 2180-2188.
31. Tawbi HA, Ahnert JR, Dummer R, Thomas AL, Granvil C, Shou Y, Dey J, Mita MM, Amakye DD, Mita AC (2011) Phase I study of LDE225 in advanced solid tumors: updated analysis of safety, preliminary efficacy, and pharmacokinetic-pharmacodynamic correlation. J Clin Oncol 29(Suppl): abstr 3062.
32. Telfer NR, Colver GB, Morton CA (2008) Guidelines for the management of basal cell carcinoma. Br J Dermatol 159: 35-48.
33. Ting PT, Kasper R, Arlette JP (2005) Metastatic basal cell carcinoma: report of two cases and literature review. J Cutan Med Surg 9: 10-15.
34. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters Jr JC, de Sauvage FJ, Low JA (2009) Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 361: 1164-1172.
35. Weinstock MA, Still JM (2011) Assessing current treatment options for patients with severe/advanced basal cell carcinoma. Semin Cutan Med Surg 30(suppl 4): S10-S13.
36. Wong CS, Strange RC, Lear JT (2003) Basal cell carcinoma. Br Med J 327: 794-798.
37. Zagrodnik B, Kempf W, Seifert B, Müller B, Burg G, Urosevic M, Dummer R (2003) Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2.
38. Cancer 98: 2708-2714.
39. Zoccali G, Pajand R, Papa P, Orsini G, Lomartire N, Giuliani M (2012) Giant basal cell carcinoma of the skin: literature review and personal experience. J Eur Acad Dermatol Venereol 26: 942-952.